Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 16971554
Liu X, Jefcoate C (2006) 2,3,7,8-tetrachlorodibenzo-p-dioxin and epidermal growth factor cooperatively suppress peroxisome proliferator-activated receptor-gamma1 stimulation and restore focal adhesion complexes during adipogenesis: selective contributions of Src, Rho, and Erk distinguish these overlapping processes in C3H10T1/2 cells. Mol Pharmacol 70, 1902-15 16971554
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

Y118-p - PXN (human)
Modsite: VGEEEHVysFPNkQk SwissProt Entrez-Gene
Orthologous residues
PXN (human): Y118‑p, PXN iso2 (human): Y118‑p, PXN iso3 (human): Y118‑p, PXN (mouse): Y118‑p, PXN iso2 (mouse): Y118‑p, PXN (rat): Y118‑p, PXN (chicken): Y118‑p, PXN (cow): Y112‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  C3H10T1/2 (fibroblast)
Cellular systems studied:  cell lines
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IBMX, dexamethasone decrease
vanadate dexamethasone, IBMX inhibit treatment-induced decrease
EGF dexamethasone, IBMX inhibit treatment-induced decrease
TCDD dexamethasone, IBMX no effect upon treatment-induced decrease
EGF, TCDD dexamethasone, IBMX inhibit treatment-induced decrease
PP2 EGF, TCDD inhibit treatment-induced increase
U0126 EGF, TCDD no effect upon treatment-induced increase

T203-p - ERK1 (mouse)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  C3H10T1/2 (fibroblast)
Cellular systems studied:  cell lines
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
IBMX, dexamethasone EGF no effect upon treatment-induced increase 20 minutes
IBMX, TCDD, dexamethasone EGF no effect upon treatment-induced increase 20 minutes
PP2 EGF inhibit treatment-induced increase
U0126 EGF inhibit treatment-induced increase
IBMX, EGF, dexamethasone increase 12-24 hours
TCDD dexamethasone, EGF, IBMX augment treatment-induced increase 12-24 hours
methyl-beta-cyclodextrin TCDD inhibit treatment-induced increase 12-24 hours

Y205-p - ERK1 (mouse)
Modsite: HtGFLtEyVAtRWyR SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  C3H10T1/2 (fibroblast)
Cellular systems studied:  cell lines
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
IBMX, dexamethasone EGF no effect upon treatment-induced increase 20 minutes
IBMX, TCDD, dexamethasone EGF no effect upon treatment-induced increase 20 minutes
PP2 EGF inhibit treatment-induced increase
U0126 EGF inhibit treatment-induced increase
IBMX, EGF, dexamethasone increase 12-24 hours
TCDD dexamethasone, EGF, IBMX augment treatment-induced increase 12-24 hours
methyl-beta-cyclodextrin TCDD inhibit treatment-induced increase 12-24 hours

T183-p - ERK2 (mouse)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  C3H10T1/2 (fibroblast)
Cellular systems studied:  cell lines
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
IBMX, dexamethasone EGF no effect upon treatment-induced increase 20 minutes
IBMX, TCDD, dexamethasone EGF no effect upon treatment-induced increase 20 minutes
PP2 EGF inhibit treatment-induced increase
U0126 EGF inhibit treatment-induced increase
IBMX, EGF, dexamethasone increase 12-24 hours
TCDD dexamethasone, EGF, IBMX augment treatment-induced increase 12-24 hours
methyl-beta-cyclodextrin TCDD inhibit treatment-induced increase 12-24 hours

Y185-p - ERK2 (mouse)
Modsite: HtGFLtEyVAtRWYR SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  C3H10T1/2 (fibroblast)
Cellular systems studied:  cell lines
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
IBMX, dexamethasone EGF no effect upon treatment-induced increase 20 minutes
IBMX, TCDD, dexamethasone EGF no effect upon treatment-induced increase 20 minutes
PP2 EGF inhibit treatment-induced increase
U0126 EGF inhibit treatment-induced increase
IBMX, EGF, dexamethasone increase 12-24 hours
TCDD dexamethasone, EGF, IBMX augment treatment-induced increase 12-24 hours
methyl-beta-cyclodextrin TCDD inhibit treatment-induced increase 12-24 hours

Y576-p - FAK (mouse)
Modsite: RyMEDstyyKASKGK SwissProt Entrez-Gene
Orthologous residues
FAK (human): Y576‑p, FAK iso2 (human): Y424‑p, FAK iso5 (human): Y576‑p, FAK (mouse): Y576‑p, FAK iso2 (mouse): Y607‑p, FAK iso4 (mouse): Y576‑p, FAK iso9 (mouse): , FAK (rat): Y576‑p, FAK (chicken): Y576‑p, FAK iso5 (chicken):
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  C3H10T1/2 (fibroblast)
Cellular systems studied:  cell lines
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IBMX, dexamethasone decrease
TCDD dexamethasone, IBMX no effect upon treatment-induced decrease
EGF dexamethasone, IBMX no effect upon treatment-induced decrease
EGF, TCDD dexamethasone, IBMX inhibit treatment-induced decrease
PP2 EGF, TCDD inhibit treatment-induced increase
U0126 EGF, TCDD inhibit treatment-induced increase

Y577-p - FAK (mouse)
Modsite: yMEDstyyKASKGKL SwissProt Entrez-Gene
Orthologous residues
FAK (human): Y577‑p, FAK iso2 (human): Y425‑p, FAK iso5 (human): Y577‑p, FAK (mouse): Y577‑p, FAK iso2 (mouse): Y608‑p, FAK iso4 (mouse): Y577‑p, FAK iso9 (mouse): , FAK (rat): Y577‑p, FAK (chicken): Y577‑p, FAK iso5 (chicken):
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  C3H10T1/2 (fibroblast)
Cellular systems studied:  cell lines
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IBMX, dexamethasone decrease
TCDD dexamethasone, IBMX no effect upon treatment-induced decrease
EGF dexamethasone, IBMX no effect upon treatment-induced decrease
EGF, TCDD dexamethasone, IBMX inhibit treatment-induced decrease
PP2 EGF, TCDD inhibit treatment-induced increase
U0126 EGF, TCDD inhibit treatment-induced increase

Y424-p - Src (mouse)
Modsite: RLIEDNEytARQGAK SwissProt Entrez-Gene
Orthologous residues
Src (human): Y419‑p, Src iso2 (human): Y425‑p, Src (mouse): Y424‑p, Src iso2 (mouse): Y418‑p, Src (rat): Y419‑p, Src (chicken): Y416‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  C3H10T1/2 (fibroblast)
Cellular systems studied:  cell lines
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PP2 increase
IBMX, EGF, dexamethasone increase
TCDD dexamethasone, EGF, IBMX no effect upon treatment-induced increase